Fovea will be responsible for worldwide development in RVO-induced macular edema.

Fovea obtained a license to develop and commercialize Dyax’ compound DX-88 in retinal diseases. The agreement gives Fovea marketing rights in the EU, while Dyax retains marketing rights for all other territories. If commercialized, each company will pay the other a tiered royalty on net sales in their respective territories.


Fovea will fund development of DX-88 for the treatment of RVO-induced macular edema (retinal vein occlusion) for approval in worldwide markets. For all other ophthalmic uses of DX-88, Fovea will be responsible for development to meet EU regulatory requirements and Dyax will take care of any additional requirements needed to obtain approval outside the EU.


“As a potent plasma kallikrein inhibitor, DX-88 has the potential to be a breakthrough therapy in reducing macular edema, a leading cause of visual loss in multiple ophthalmic diseases,” explains Bernard Gilly, president and CEO of Fovea.



To comment on this story, go to BLOGbiotech.

Previous articlePromega and Celsis to Provide Solutions for ADME/Tox Testing in Primary Hepatocytes
Next articleInvestigators Identify Glutathione as a Marker for Mitochondrial Disorders